A Bagust

5.0k total citations
97 papers, 3.6k citations indexed

About

A Bagust is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A Bagust has authored 97 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Economics and Econometrics and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A Bagust's work include Health Systems, Economic Evaluations, Quality of Life (22 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (11 papers). A Bagust is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (22 papers), Lung Cancer Treatments and Mutations (15 papers) and Lung Cancer Diagnosis and Treatment (11 papers). A Bagust collaborates with scholars based in United Kingdom, United States and Netherlands. A Bagust's co-authors include Sophie Beale, Angela Boland, Y Dündar, Rumona Dickson, John Posnett, Maurice Place, T Walley, Alan Haycox, C McLeod and P. K. Hopkinson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

A Bagust

95 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A Bagust United Kingdom 36 939 662 535 506 491 97 3.6k
Marshall M. Joffe United States 45 710 0.8× 986 1.5× 1.1k 2.0× 1.0k 2.0× 467 1.0× 113 8.5k
Christopher Hyde United Kingdom 39 497 0.5× 509 0.8× 597 1.1× 1.1k 2.2× 551 1.1× 115 5.6k
Adrian R. Levy Canada 37 844 0.9× 186 0.3× 454 0.8× 847 1.7× 313 0.6× 141 4.1k
Onur Başer United States 34 633 0.7× 536 0.8× 430 0.8× 847 1.7× 600 1.2× 193 4.1k
Ken Redekop Netherlands 40 1.3k 1.4× 813 1.2× 497 0.9× 815 1.6× 379 0.8× 243 6.4k
J. Chilcott United Kingdom 39 1.2k 1.2× 295 0.4× 548 1.0× 948 1.9× 701 1.4× 145 4.4k
Joerg Hasford Germany 41 409 0.4× 240 0.4× 668 1.2× 466 0.9× 1.3k 2.7× 188 7.0k
Ross Lawrenson New Zealand 29 212 0.2× 755 1.1× 371 0.7× 434 0.9× 809 1.6× 225 3.7k
Alexander Turchin United States 32 499 0.5× 1.1k 1.6× 245 0.5× 908 1.8× 143 0.3× 119 4.0k
William F. Owen United States 41 561 0.6× 284 0.4× 777 1.5× 1.1k 2.2× 182 0.4× 111 5.8k

Countries citing papers authored by A Bagust

Since Specialization
Citations

This map shows the geographic impact of A Bagust's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Bagust with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Bagust more than expected).

Fields of papers citing papers by A Bagust

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Bagust. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Bagust. The network helps show where A Bagust may publish in the future.

Co-authorship network of co-authors of A Bagust

This figure shows the co-authorship network connecting the top 25 collaborators of A Bagust. A scholar is included among the top collaborators of A Bagust based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Bagust. A Bagust is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleeman, Nigel, Rachel Houten, A Bagust, et al.. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment. 24(2). 1–180. 30 indexed citations
2.
Stainthorpe, Angela, J Greenhalgh, A Bagust, et al.. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 36(10). 1153–1163. 11 indexed citations
3.
4.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma. PharmacoEconomics. 31(5). 403–413. 24 indexed citations
5.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technology Assessment. 15(31). 1–178. 25 indexed citations
6.
Sacco, Joseph J., et al.. (2010). The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study. PLoS ONE. 5(1). e8933–e8933. 166 indexed citations
7.
8.
Bagust, A, J Greenhalgh, Angela Boland, et al.. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. PharmacoEconomics. 28(6). 439–448. 36 indexed citations
9.
10.
Palmer, Andrew, Valentine Wn, P McEwan, et al.. (2007). 'Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting'. Diabetes Care. 30(6). 1638–1646. 178 indexed citations
11.
Black, Corri, A Bagust, Angela Boland, et al.. (2006). The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews. Health Technology Assessment. 10(3). iii–iv, ix. 46 indexed citations
12.
Beale, Sophie, et al.. (2006). Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK. PharmacoEconomics. 24(S1). 21–34. 19 indexed citations
13.
Strobl, Judith, A Bagust, Alan Haycox, et al.. (2003). Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry. Pharmacoepidemiology and Drug Safety. 12(6). 467–473. 7 indexed citations
14.
Sundberg, Gun, A Bagust, & Andreas Terént. (2002). A model for costs of stroke services. Health Policy. 63(1). 81–94. 35 indexed citations
15.
Bagust, A, et al.. (2001). An economic model of the long-term health care burden of Type II diabetes. Diabetologia. 44(12). 2140–2155. 85 indexed citations
16.
Hughes, Dyfrig, A Bagust, Alan Haycox, & Tom Walley. (2001). The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: a review of the literature. Health Economics. 10(7). 601–615. 134 indexed citations
17.
Bagust, A, et al.. (2001). Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials. European Journal of Cancer. 37(9). 1081–1088. 7 indexed citations
18.
Bagust, A, Maurice Place, & John Posnett. (1999). Dynamics of bed use in accommodating emergency admissions: stochastic simulation model. BMJ. 319(7203). 155–158. 347 indexed citations
19.
Haycox, Alan, A Bagust, & Thomas Walley. (1999). Clinical guidelines---the hidden costs. BMJ. 318(7180). 391–393. 51 indexed citations
20.
Bagust, A, et al.. (1992). Quality or quantity.. PubMed. 102(5314). 23–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marshall M. Joffe Breakdown of academic impact, for papers by Christopher Hyde Breakdown of academic impact, for papers by Adrian R. Levy Breakdown of academic impact, for papers by Onur Başer Breakdown of academic impact, for papers by Ken Redekop Breakdown of academic impact, for papers by J. Chilcott Breakdown of academic impact, for papers by Joerg Hasford Breakdown of academic impact, for papers by Ross Lawrenson Breakdown of academic impact, for papers by Alexander Turchin Breakdown of academic impact, for papers by William F. Owen
Rankless by CCL
2026